DOI : https://doi.org/10.29165/ajarcde.v9i3.861

Bioavailability of Curcumin in Various Nanoformulations: A Critical Review

Paulus Risan F Lalong (1), Cesar Welya Refdi (2), Suryani Une (3), Mohammad Sayuti (4), Didik Iswadi (5)
(1) Doctoral Program in Food Science, Graduate School, IPB University, Bogor, Indonesia and Department of Food Technology, Faculty of Science and Technology, Widya Mandira Catholic University, Kupang, Indonesia
(2) Doctoral Program in Food Science, Graduate School, IPB University, Bogor, Indonesia and Department of Food Technology and Agricultural Products, Faculty of Agricultural Technology, Andalas University, Padang, Indonesia
(3) Doctoral Program in Food Science, Graduate School, IPB University, Bogor, Indonesia and Department of Food Technology, Faculty of Agriculture, Gorontalo State University, Indonesia
(4) Department of Fish Processing Technology, Jakarta Technical University of Fisheries, Indonesia
(5) Doctoral Program in Food Science, Graduate School, IPB University, Bogor, Indonesia and Department of Chemical Engineering Study, Faculty of Engineering, Pamulang University, Indonesia
Fulltext View | Download
How to cite (AJARCDE) :
Lalong, P. R. F., Refdi, C. W., Une, S., Sayuti, M., & Iswadi, D. (2025). Bioavailability of Curcumin in Various Nanoformulations: A Critical Review. AJARCDE (Asian Journal of Applied Research for Community Development and Empowerment), 9(3), 409–416. https://doi.org/10.29165/ajarcde.v9i3.861
Citation Format :

The critical review aimed to assess the enhancement of curcumin bioavailability through nanoformulation-based delivery systems, summarize comparative pharmacokinetic and in vivo safety data, and identify significant obstacles to the clinical translation of curcumin. This study identified articles from Scopus, Elsevier (via ScienceDirect), and PubMed that were published between 2015 and 2025. We used keyword combinations such as curcumin, nanoformulation, nanoparticles, bioavailability, pharmacokinetics, toxicity/safety, and clinical translation to identify them. Furthermore, a comparison was made between peer-reviewed studies that were eligible based on the type of nanoformulation, the reported fold-increase in bioavailability, tolerability in vivo, and the limitations of translation. Nanoparticles (e.g., PLGA, chitosan), solid lipid nanoparticles, micelles, nanoemulsions, nanogels, cyclodextrin complexes, phytosomes, dendrimers, metallic nanoparticles, niosomes, and exosomes exhibit mechanisms that enhance solubility, provide protection against degradation, improve permeability, and facilitate sustained or targeted delivery. The data demonstrate that various nanoformulations can enhance systemic exposure from moderate to substantial levels, depending on the formulation and study design, with lipid-polymer-based systems often exhibiting significant enhancements. Studies generally report acceptable safety at therapeutic doses; however, dose dependence, formulation-specific effects, limited long-term human data, manufacturing scalability, and evolving regulatory requirements continue to constrain clinical adoption. Enhance curcumin's bioavailability and therapeutic efficacy; however, standardized manufacturing, thorough safety assessment, and robust clinical trials are necessary to facilitate its integration into standard practice.
Contribution to Sustainable Development Goals (SDGs):
SDG 3: Good Health and Well Being
SDG 9: Industry, Innovation and Infrastructure
SDG 12: Responsible Consumption and Production
SDG 17: Partnerships for the Goals

[1] A. Karthikeyan, N. Senthil, and T. Min, “Nanocurcumin: A Promising Candidate for Therapeutic Applications,” Front. Pharmacol., vol. 11, 2020, doi: 10.3389/fphar.2020.00487.

[2] S. Stohs, O. Chen, S. Ray, J. Ji, L. Bucci, and H. Preuss, “Highly Bioavailable Forms of Curcumin and Promising Avenues for Curcumin-Based Research and Application: A Review,” Molecules, vol. 25, 2020, doi: 10.3390/molecules25061397.

[3] M. M. Nasery et al., “Curcumin Delivery Mediated by Bio-Based Nanoparticles: A Review,” Molecules, vol. 25, 2020, doi: 10.3390/molecules25030689.

[4] M. Yallapu, P. Nagesh, M. Jaggi, and S. Chauhan, “Therapeutic Applications of Curcumin Nanoformulations,” AAPS J., vol. 17, pp. 1341–1356, 2015, doi: 10.1208/s12248-015-9811-z.

[5] Z. Rafiee, M. Nejatian, M. Daeihamed, and S. Mahdi, “Trends in Food Science & Technology Application of curcumin-loaded nanocarriers for food , drug and cosmetic purposes,” Trends Food Sci. Technol., vol. 88, no. April, pp. 445–458, 2019, doi: 10.1016/j.tifs.2019.04.017.

[6] W. Liu et al., “Oral bioavailability of curcumin: problems and advancements,” J. Drug Target., vol. 24, pp. 694–702, 2016, doi: 10.3109/1061186x.2016.1157883.

[7] L. Slika and D. Patra, A short review on chemical properties, stability and nano-technological advances for curcumin delivery, vol. 17, no. 1. Taylor & Francis, 2020. doi: 10.1080/17425247.2020.1702644.

[8] T. Jiang, W. Liao, and C. Charcosset, “Recent advances in encapsulation of curcumin in nanoemulsions: A review of encapsulation technologies, bioaccessibility and applications,” Food Res. Int., vol. 132, no. October 2019, p. 109035, 2020, doi: 10.1016/j.foodres.2020.109035.

[9] N. D’Angelo et al., “Curcumin encapsulation in nanostructures for cancer therapy: a 10-year overview.,” Int. J. Pharm., p. 120534, 2021, doi: 10.1016/j.ijpharm.2021.120534.

[10] S. Jacob et al., “Advances in Nanocarrier Systems for Overcoming Formulation Challenges of Curcumin: Current Insights,” Nanomaterials, vol. 14, 2024, doi: 10.3390/nano14080672.

[11] Z. Liu, J. Smart, and A. Pannala, “Recent developments in formulation design for improving oral bioavailability of curcumin: A review,” J. Drug Deliv. Sci. Technol., 2020, doi: 10.1016/j.jddst.2020.102082.

[12] M. Moniruzzaman and T. Min, “Curcumin, curcumin nanoparticles and curcumin nanospheres: A review on their pharmacodynamics based on monogastric farm animal, poultry and fish nutrition,” Pharmaceutics, vol. 12, no. 5, 2020, doi: 10.3390/pharmaceutics12050447.

[13] B. A. Hailu, G. G. Bogale, and J. Beyene, “Spatial heterogeneity and factors influencing stunting and severe stunting among under-5 children in Ethiopia: spatial and multilevel analysis,” 2020, Springer Science and Business Media LLC. doi: 10.1038/s41598-020-73572-5.

[14] K. Khezri, M. Saeedi, H. Mohammadamini, and A. S. Zakaryaei, “A comprehensive review of the therapeutic potential of curcumin nanoformulations,” Phyther. Res., vol. 35, no. 10, pp. 5527–5563, 2021, doi: 10.1002/ptr.7190.

[15] M. Bagheri, C. F. Van Nostrum, R. J. Kok, G. Storm, W. E. Hennink, and M. Heger, “Utility of Intravenous Curcumin Nanodelivery Systems for Improving In Vivo Pharmacokinetics and Anticancer Pharmacodynamics,” Mol. Pharm., vol. 19, no. 9, pp. 3057–3074, 2022, doi: 10.1021/acs.molpharmaceut.2c00455.

[16] K. E. Wong, S. Ngai, K.-G. Chan, L. Lee, B. Goh, and L. Chuah, “Curcumin Nanoformulations for Colorectal Cancer: A Review,” Front. Pharmacol., vol. 10, 2019, doi: 10.3389/fphar.2019.00152.

[17] V. Ipar, A. Dsouza, and P. Devarajan, “Enhancing Curcumin Oral Bioavailability Through Nanoformulations,” Eur. J. Drug Metab. Pharmacokinet., vol. 44, pp. 459–480, 2019, doi: 10.1007/s13318-019-00545-z.

[18] H. Wahnou, R. El Kebbaj, B. Liagre, V. Sol, Y. Limami, and R. Duval, “Curcumin-Based Nanoparticles: Advancements and Challenges in Tumor Therapy,” Pharmaceutics, vol. 17, 2025, doi: 10.3390/pharmaceutics17010114.

[19] G. M. Pontes-Quero, L. Benito-Garzón, J. P. Cano, M. Aguilar, and B. Vázquez-Lasa, “Amphiphilic polymeric nanoparticles encapsulating curcumin: Antioxidant, anti-inflammatory and biocompatibility studies.,” Mater. Sci. Eng. C. Mater. Biol. Appl., vol. 121, p. 111793, 2020, doi: 10.1016/j.msec.2020.111793.

[20] C. Ban et al., “Enhancing the oral bioavailability of curcumin using solid lipid nanoparticles.,” Food Chem., vol. 302, p. 125328, 2019, doi: 10.1016/j.foodchem.2019.125328.

[21] A. Babaei et al., “Development and Optimization of Curcumin-Loaded Solid Lipid Nanoparticles Using Box-Behnken Design and Evaluation of Its Efficacy in Modulating Morphine-Induced Conditioned Place Preference: In Vivo and In Silico Studies.,” J. Drug Target., pp. 1–29, 2025, doi: 10.1080/1061186x.2025.2468758.

[22] S. Sharma, U. Lal, and T. Bal, “pH-sensitive polymeric micelles of polyvinyl acetate grafted neem gum amphiphilic graft copolymer for curcumin delivery.,” Int. J. Biol. Macromol., vol. 303, p. 140574, 2025, doi: 10.1016/j.ijbiomac.2025.140574.

[23] B. Zheng, S. Peng, X. Zhang, and D. Mcclements, “Impact of Delivery System Type on Curcumin Bioaccessibility: Comparison of Curcumin-Loaded Nanoemulsions with Commercial Curcumin Supplements.,” J. Agric. Food Chem., vol. 66 41, pp. 10816–10826, 2018, doi: 10.1021/acs.jafc.8b03174.

[24] M. Ciuca and R. Racovita, “Curcumin: Overview of Extraction Methods, Health Benefits, and Encapsulation and Delivery Using Microemulsions and Nanoemulsions,” Int. J. Mol. Sci., vol. 24, 2023, doi: 10.3390/ijms24108874.

[25] Y. Chen et al., “Cyclodextrin-based metal-organic framework nanoparticles as superior carriers for curcumin: Study of encapsulation mechanism, solubility, release kinetics, and antioxidative stability.,” Food Chem., vol. 383, p. 132605, 2022, doi: 10.1016/j.foodchem.2022.132605.

[26] S. Fiani, F. Maestrelli, L. Micheli, M. Cirri, N. Mennini, and P. Mura, “Curcumin’s niosomes coated with chitosan for the treatment of osteoarthritis: effect of cyclodextrin complexation.,” Int. J. Pharm., p. 125933, 2025, doi: 10.1016/j.ijpharm.2025.125933.

[27] A. A. Targhi et al., “Synergistic effect of curcumin-Cu and curcumin-Ag nanoparticle loaded niosome: Enhanced antibacterial and anti-biofilm activities.,” Bioorg. Chem., vol. 115, p. 105116, 2021, doi: 10.1016/j.bioorg.2021.105116.

[28] M. S. Razavi, P. Ebrahimnejad, Y. Fatahi, A. D’emanuele, and R. Dinarvand, “Recent Developments of Nanostructures for the Ocular Delivery of Natural Compounds,” Front. Chem., vol. 10, 2022, doi: 10.3389/fchem.2022.850757.

[29] H. Ji, J. Tang, M. Li, J. Ren, N. Zheng, and L. Wu, “Curcumin-loaded solid lipid nanoparticles with Brij78 and TPGS improved in vivo oral bioavailability and in situ intestinal absorption of curcumin,” Drug Deliv., vol. 23, pp. 459–470, 2016, doi: 10.3109/10717544.2014.918677.

[30] T. Gupta, J. Singh, S. Kaur, S. Sandhu, G. Singh, and I. Kaur, “Enhancing Bioavailability and Stability of Curcumin Using Solid Lipid Nanoparticles (CLEN): A Covenant for Its Effectiveness,” Front. Bioeng. Biotechnol., vol. 8, 2020, doi: 10.3389/fbioe.2020.00879.

[31] A. Brotons-Canto, C. González-Navarro, A. Gil, E. Asín-Prieto, M. Saiz, and J. M. Llabrés, “Zein Nanoparticles Improve the Oral Bioavailability of Curcumin in Wistar Rats,” Pharmaceutics, vol. 13, 2021, doi: 10.3390/pharmaceutics13030361.

[32] S. Peng, Z.-L. Li, L. Zou, W. Liu, C.-M. Liu, and D. Mcclements, “Improving curcumin solubility and bioavailability by encapsulation in saponin-coated curcumin nanoparticles prepared using a simple pH-driven loading method.,” Food Funct., vol. 9 3, pp. 1829–1839, 2018, doi: 10.1039/c7fo01814b.

[33] R. Tabanelli, S. Brogi, and V. Calderone, “Improving Curcumin Bioavailability: Current Strategies and Future Perspectives,” Pharmaceutics, vol. 13, 2021, doi: 10.3390/pharmaceutics13101715.

[34] J. Shaikh, D. Ankola, V. Beniwal, D. Singh, and M. Kumar, “Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer.,” Eur. J. Pharm. Sci., vol. 37 3–4, pp. 223–230, 2009, doi: 10.1016/j.ejps.2009.02.019.

[35] T. Kanwal et al., “Design of absorption enhancer containing self-nanoemulsifying drug delivery system (SNEDDS) for curcumin improved anti-cancer activity and oral bioavailability,” J. Mol. Liq., p. 114774, 2020, doi: 10.1016/j.molliq.2020.114774.

[36] C. Bertoncini-Silva, A. Vlad, R. Ricciarelli, P. G. Fassini, V. Suen, and J. Zingg, “Enhancing the Bioavailability and Bioactivity of Curcumin for Disease Prevention and Treatment,” Antioxidants, vol. 13, 2024, doi: 10.3390/antiox13030331.

[37] H. Nsairat, D. Khater, U. Sayed, F. Odeh, A. Al, and W. Alshaer, “Heliyon Liposomes?: structure , composition , types , and clinical applications ?,” HLY, vol. 8, no. 5, p. e09394, 2022, doi: 10.1016/j.heliyon.2022.e09394.

[38] E. Namiot, A. Sokolov, V. Chubarev, V. Tarasov, and H. Schiöth, “Nanoparticles in Clinical Trials: Analysis of Clinical Trials, FDA Approvals and Use for COVID-19 Vaccines,” Int. J. Mol. Sci., vol. 24, 2023, doi: 10.3390/ijms24010787.

[39] H. Nsairat, D. Khater, U. Sayed, F. Odeh, A. Bawab, and W. Alshaer, “Liposomes: structure, composition, types, and clinical applications,” Heliyon, vol. 8, 2022, doi: 10.1016/j.heliyon.2022.e09394.

[40] M. Mehta, T. A. Bui, X. Yang, Y. Aksoy, E. Goldys, and W. Deng, “Lipid-Based Nanoparticles for Drug/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development,” ACS Mater. Au, vol. 3, pp. 600–619, 2023, doi: 10.1021/acsmaterialsau.3c00032.

[41] A. Mohanty, S. Uthaman, and I. Park, “Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy,” Molecules, vol. 25, 2020, doi: 10.3390/molecules25194377.

[42] Y. Seo et al., “Recent Progress of Lipid Nanoparticles-Based Lipophilic Drug Delivery: Focus on Surface Modifications,” Pharmaceutics, vol. 15, 2023, doi: 10.3390/pharmaceutics15030772.

[43] D. Sivadasan, M. Sultan, O. Madkhali, Y. Almoshari, and N. Thangavel, “Polymeric Lipid Hybrid Nanoparticles (PLNs) as Emerging Drug Delivery Platform—A Comprehensive Review of Their Properties, Preparation Methods, and Therapeutic Applications,” Pharmaceutics, vol. 13, 2021, doi: 10.3390/pharmaceutics13081291.

[44] M. Rakotoarisoa, B. Angelov, V. Garamus, and A. Angelova, “Curcumin- and Fish Oil-Loaded Spongosome and Cubosome Nanoparticles with Neuroprotective Potential against H2O2-Induced Oxidative Stress in Differentiated Human SH-SY5Y Cells,” ACS Omega, 2019, doi: 10.1021/acsomega.8b03101.

[45] A. Ombredane et al., “In Vivo Efficacy and Toxicity of Curcumin Nanoparticles in Breast Cancer Treatment: A Systematic Review,” Front. Oncol., vol. 11, 2021, doi: 10.3389/fonc.2021.612903.

[46] O. Oyeyemi et al., “Curcumin-Artesunate Based Polymeric Nanoparticle; Antiplasmodial and Toxicological Evaluation in Murine Model,” Front. Pharmacol., vol. 9, 2018, doi: 10.3389/fphar.2018.00562.

[47] P. Dandekar, R. Dhumal, R. Jain, D. Tiwari, G. Vanage, and V. Patravale, “Toxicological evaluation of pH-sensitive nanoparticles of curcumin: acute, sub-acute and genotoxicity studies.,” Food Chem. Toxicol., vol. 48 8–9, pp. 2073–2089, 2010, doi: 10.1016/j.fct.2010.05.008.

[48] A. Luss et al., “Toxicity Evaluation and Controlled-Release of Curcumin-Loaded Amphiphilic Poly-N-vinylpyrrolidone Nanoparticles: In Vitro and In Vivo Models,” Pharmaceutics, vol. 16, 2023, doi: 10.3390/pharmaceutics16010008.

[49] Z. Busari et al., “Antiplasmodial Activity and Toxicological Assessment of Curcumin PLGA-Encapsulated Nanoparticles,” Front. Pharmacol., vol. 8, 2017, doi: 10.3389/fphar.2017.00622.

[50] F. Sha’at et al., “Fabrication and Evaluation of Polyhydroxyalkanoate-Based Nanoparticles for Curcumin Delivery in Biomedical Applications,” Molecules, vol. 30, 2025, doi: 10.3390/molecules30061216.

[51] N. Ibrahim, H. Shawky, A. Maghraby, and E. Farrag, “Insights into the Pharmacokinetics, Biodistribution, and Oral Toxicity of a Polymeric Benzimidazole - Curcumin Nanocomplex with a Multitarget Anticancer Potential.,” Food Chem. Toxicol., p. 115483, 2025, doi: 10.1016/j.fct.2025.115483.

[52] Y.-S. Liu et al., “Dual Drug-Loaded Nanoliposomes Encapsulating Curcumin and 5-Fluorouracil with Advanced Medicinal Applications: Self-Monitoring and Antitumor Therapy,” Molecules, vol. 28, 2023, doi: 10.3390/molecules28114353.

[53] J.-W. Song, Y.-S. Liu, Y. Guo, Y.-P. Guo, and L. Guo, “Nano–Liposomes Double Loaded with Curcumin and Tetrandrine: Preparation, Characterization, Hepatotoxicity and Anti–Tumor Effects,” Int. J. Mol. Sci., vol. 23, 2022, doi: 10.3390/ijms23126858.

[54] S. N. S. Abdullah, K. Subramaniam, Z. H. M. Zamani, S. Sarchio, F. M. Yasin, and S. Shamsi, “Biocompatibility Study of Curcumin-Loaded Pluronic F127 Nanoformulation (NanoCUR) against the Embryonic Development of Zebrafish (Danio rerio),” Molecules, vol. 27, 2022, doi: 10.3390/molecules27144493.

[55] Xuan-Hai et al., “Differential Cytotoxicity of Curcumin-Loaded Micelles on Human Tumor and Stromal Cells,” Int. J. Mol. Sci., vol. 23, 2022, doi: 10.3390/ijms232012362.

[56] S. Guerrero et al., “Curcumin-loaded nanoemulsion: a new safe and effective formulation to prevent tumor reincidence and metastasis.,” Nanoscale, vol. 10 47, pp. 22612–22622, 2018, doi: 10.1039/c8nr06173d.

[57] N. Elbialy, S. Aboushoushah, and W. Alshammari, “Long-term biodistribution and toxicity of curcumin capped iron oxide nanoparticles after single-dose administration in mice.,” Life Sci., vol. 230, pp. 76–83, 2019, doi: 10.1016/j.lfs.2019.05.048.

[58] S. H. Ghoran, A. Calcaterra, M. Abbasi, F. Taktaz, K. Nieselt, and E. Babaei, “Curcumin-Based Nanoformulations: A Promising Adjuvant towards Cancer Treatment,” Molecules, vol. 27, 2022, doi: 10.3390/molecules27165236.

[59] H. Sun et al., “Modulation of Macrophages Using Nanoformulations with Curcumin to Treat Inflammatory Diseases: A Concise Review,” Pharmaceutics, vol. 14, 2022, doi: 10.3390/pharmaceutics14102239.

[60] M. Boroughani et al., “Nanocurcumin in cancer treatment: a comprehensive systematic review,” Discov. Oncol., vol. 15, 2024, doi: 10.1007/s12672-024-01272-x.

[61] H. Amekyeh, E. Alkhader, R. Sabra, and N. Billa, “Prospects of Curcumin Nanoformulations in Cancer Management,” Molecules, vol. 27, 2022, doi: 10.3390/molecules27020361.

Downloads

Download data is not yet available.